Stock analysts at HC Wainwright issued their FY2029 EPS estimates for Olema Pharmaceuticals in a research report issued on ...

Research analysts at HC Wainwright cut their Q2 2025 EPS estimates for shares of Bitcoin Depot in a note issued to investors ...

Fintel reports that on March 21, 2025, HC Wainwright & Co. downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Buy to ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherapeutics (BRNS – Research Report) today and set a price target of ...

H.C. Wainwright downgraded Optinose (OPTN) to Neutral from Buy with a $9 price target after Paratek Pharmaceuticals announced it will be ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

On Friday, H.C. Wainwright reaffirmed a Neutral stock rating for Adicet Bio Inc. (NASDAQ:ACET), a biotechnology company focused on the development of therapies for cancer and other diseases.

Fireside chat Damian Marron, interim CEO, will participate in a fireside chat moderated by Joe Pantginis, Managing Director, Equity Research at H.C. Wainwright & Co., LLC. March 27 at 08.00am EST ...